Inhibition of lymphatic metastasis in neuroblastoma by a novel neutralizing antibody to vascular endothelial growth factor-D

Cancer Science

Volumn 103, Issue 12, 2012, Pages 2144-2152

  Kashima, Kenji ^a   Watanabe, Miho ^a   Satoh, Yasuko ^a   Hata, Junichi ^a   Ishii, Nobuya ^a   Aoki, Yuko ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CVE 199; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR D MONOCLONAL ANTIBODY; VASCULOTROPIN D;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE CELL; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; FEMALE; HUMANS; LYMPHATIC METASTASIS; MICE; MICE, INBRED BALB C; NEUROBLASTOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84870687721     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12010     Document Type: Article

References (34)

1. Liotta LA. Cancer cell invasion and metastasis. Sci Am 1992; 266: 54-9, 62-3.
2. Qin LX, Tang ZY. The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 193-9.
3. Ghaferi AA, Wong SL, Johnson TM et al. Prognostic significance of a positive nonsentinel lymph node in cutaneous melanoma. Ann Surg Oncol 2009; 16: 2978-84.
4. Grandi C, Alloisio M, Moglia D et al. Prognostic significance of lymphatic spread in head and neck carcinomas: therapeutic implications. Head Neck Surg 1985; 8: 67-73.
5. de Manzoni G, Verlato G, Guglielmi A, Laterza E, Genna M, Cordiano C. Prognostic significance of lymph node dissection in gastric cancer. Br J Surg 1996; 83: 1604-7.
6. Lughezzani G, Capitanio U, Jeldres C et al. Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: a population-based perspective. Cancer 2009; 115: 5680-7.
7. Tuna S, Dalkilic Calis M, Sakar B, Aykan F, Camlica H, Topuz E. Prognostic significance of the metastatic lymph node ratio for survival in colon cancer. J BUON 2011; 16: 478-85.
8. Nguyen TH. Mechanisms of metastasis. Clin Dermatol 2004; 22: 209-16.
9. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004; 4: 448-56.
10. Raica M, Ribatti D. Targeting tumor lymphangiogenesis: an update. Curr Med Chem 2010; 17: 698-708.
11. Stacker SA, Stenvers K, Caesar C et al. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J Biol Chem 1999; 274: 32127-36.
12. Achen MG, Jeltsch M, Kukk E et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 1998; 95: 548-53.
13. Saharinen P, Tammela T, Karkkainen MJ, Alitalo K. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 2004; 25: 387-95.
14. Veikkola T, Jussila L, Makinen T et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 2001; 20: 1223-31.
15. Achen MG, Stacker SA. Molecular control of lymphatic metastasis. Ann N Y Acad Sci 2008; 1131: 225-34.
16. White JD, Hewett PW, Kosuge D et al. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res 2002; 62: 1669-75.
17. Nakamura Y, Yasuoka H, Tsujimoto M et al. Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up. Clin Cancer Res 2003; 9: 716-21.
18. Yokoyama Y, Charnock-Jones DS, Licence D et al. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. Clin Cancer Res 2003; 9: 1361-9.
19. Yokoyama Y, Charnock-Jones DS, Licence D et al. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer 2003; 88: 237-44.
20. Juttner S, Wissmann C, Jons T et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 2006; 24: 228-40.
21. Liu B, Ma J, Wang X et al. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma. Anat Rec (Hoboken) 2008; 291: 1227-35.
22. Ono N, Yamazaki T, Nakanishi Y et al. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. Cancer Sci 2012; 103: 342-9.
23. Kirkin V, Mazitschek R, Krishnan J et al. Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2. Eur J Biochem 2001; 268: 5530-40.
24. Thelen A, Scholz A, Benckert C et al. VEGF-D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma. Int J Cancer 2008; 122: 2471-81.
25. Leppanen VM, Jeltsch M, Anisimov A et al. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood 2011; 117: 1507-15.
26. Stacker SA, Caesar C, Baldwin ME et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001; 7: 186-91.
27. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-10.
28. Yashiro M, Shinto O, Nakamura K et al. Effects of VEGFR-3 phosphorylation inhibitor on lymph node metastasis in an orthotopic diffuse-type gastric carcinoma model. Br J Cancer 2009; 101: 1100-6.
29. Wong SY, Haack H, Crowley D, Barry M, Bronson RT, Hynes RO. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Res 2005; 65: 9789-98.
30. Detmar M, Hirakawa S. The formation of lymphatic vessels and its importance in the setting of malignancy. J Exp Med 2002; 196: 713-8.
31. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369: 2106-20.
32. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010; 362: 2202-11.
33. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-16.
34. Modak S, Cheung NK. Neuroblastoma: therapeutic strategies for a clinical enigma. Cancer Treat Rev 2010; 36: 307-17.